Science

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

Al-Ola Abdallah/LinkedIn

May 1, 2025, 10:25

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared an article by Donald Waddell, et al. on X:

“Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.

TPO-RAs did not increase the rate of thrombocytopenia resolution relative to supportive care.
Adverse effects requiring therapy modification related to TPO-RAs occurred in 25% of patients.
The financial toxicity associated with TPO-RAs was roughly $87,000.”

Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.

Authors: Donald Waddell, Jennifer Collins, Sarvnaz Sadrameli

You can Read the Full Article on Journal of Transplantation and Cellular Therapy.

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

More posts featuring Al-Ola A Abdallah.

Al-Ola A Abdallah cancer Donald Waddell fight against cancer Global fight against cancer Jennifer Collins OncoDaily Oncology Plasma Cell disorder program Sarvnaz Sadrameli T-cell therapy Thrombocytopenia Thrombopoietin TPO-RAs transplantation and cellular therapy University of Kansas Medical Center

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Robin Zon: The Official End of My Term as ASCO President